A multi-centers, placebo-controlled, randomized, double-blinded, pilot clinical trial is designed to evaluate the safety of the DA-3030 injection and to explore the efficacy for Neuropathic pain.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
31
Hanyang University Medical Center
Seoul, South Korea
Abnormal score of vital signs measured by following methods: two-sample t-test, Wilcoxon rank sum test, Paired t- test, Wilcoxon signed rank test, McNemar test, Chi-squared test, or/and Fisher's exact test
Time frame: 12 Weeks
Number of Subjects or Incidence with Adverse Events including Adverse Drug Event and Serious Adverse Event
Time frame: 12 weeks
Average pain score
Measuring how much the subject feels pain last 24 hours on a scale of one to ten (no pain - most severe pain)
Time frame: 12 Weeks
Most severe pain score
Measuring how much the subject feels pain last 24 hours on a scale of one to ten (no pain - most severe pain)
Time frame: 12 weeks
overnight pain score
Measuring how much the subject feels pain last night on a scale of one to ten (no pain - most severe pain)
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.